Streetwise Reports' Article Archives — August 2022 back to current month (41)
FDA OKs Biopharma to Trial New Cell Therapy (08/30/2022)
Now with clearance, the firm plans to commence a Phase 1 study of its lead candidate in patients with lymphoma by the end of this year, noted an H.C. Wainwright & Co. report.
Shares of OKYO Pharma Ltd. traded 23% higher after the company reported it intends to submit an IND to the U.S. FDA for its OK-101 for treating dry eye disease in Q4/22. Together with its manufacturing partner, AmbioPharm Inc., the firm is now preparing to initiate a phase 2 clinical study in Q1/23.
The developer of genetic medicines is taking six more months to conduct longer preclinical safety studies involving its lead therapeutic, noted an Oppenheimer report.
ACC Recommends Approved Drug for Lowering LDL (08/29/2022)
This same medicine is currently being evaluated in a global clinical trial from which topline results are expected in Q1/23, noted an H.C. Wainwright & Co. report.
Pharma Co. To Provide HHS With Smallpox Drug (08/29/2022)
Chimerix Inc. shares traded 8% higher after the company reported it has entered into a 10-year, $680 million contract with a U.S. Government health agency to deliver up to 1.7 million treatment courses of its TEMBEXA for use as a medical countermeasure for smallpox.
A small biotech has taken further steps to deepen the intellectual property moat for its potentially revolutionary treatment for alcohol addiction. Find out which company it is and why one analyst has given it a CA$8 target price.
Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report.
The U.S. Food and Drug Administration's follow-up to the new drug application for this potential treatment suggests a possible green light based on unmet medical need, noted a BTIG report.
Hedge Fund Doubles Position in Biotech Co. (08/23/2022)
A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price — a 560% increase from the unit price in its recent placement.
Expert Sees Even More 'Good News' From Pharma Co. (08/23/2022)
Expert Clive Maund reviews the latest news with Algernon Pharmaceuticals Inc., including the recent successful closing of its financing.
Biotech Co. Has Multiple Shots on Goal (08/22/2022)
This developer of immunotherapies has a robust pipeline, several active clinical programs and, thus, numerous catalysts, noted an Oppenheimer report.
Price Target on Cancer Drug Co. Boosted (08/22/2022)
The price target was increased by 66% to reflect the full potential opportunity of the biopharma's drug candidate for hepatocellular carcinoma, a key driver going forward, noted an H.C. Wainwright & Co. report.
Drug Developer Initiates Ph. 3 STGD1 Trial (08/22/2022)
Shares of Belite Bio Inc. traded 19% higher after the company reported it has initiated a pivotal Phase 3 clinical study in the U.S. for its LBS-008 for use in treating Stargardt disease.
Biopharma Co. Gains FDA Approval for Oral MDD Drug (08/19/2022)
Shares of Axsome Therapeutics Inc. traded 39% higher after the company reported that the U.S. FDA granted approval for its AUVELITY™ making it the first oral N-methyl D-aspartate (NMDA) receptor antagonist authorized for treating major depressive disorder in adults.
One healthcare company in the U.K. is bringing its proprietary Ketamine-assisted treatment for Alcohol Use Disorder to Canada. It's the second deal the company has made with a North American clinic operator this week. Find out why this won't be the last one.
Biotech Co. To Receive 66% Funding From UK Gov. (08/17/2022)
Expert Clive Maund reviews the latest update with Awakn Life Sciences Corp., including its recent rise in stock volume and the announcement that the company is to receive 66% funding support from the UK government for the development of its ketamine-assisted therapy treatment for alcohol use disorders.
This sale indicates the firm is continuing to forge a pathway into one of its large target markets, noted a Noble Capital Markets report.
In landing this first licensing deal, the life sciences firm "shows good progress towards a potentially high-margin business," noted a Stifel report.
Nuvectis Pharma Inc recently announced quarterly financial results and is continuing to advance its precision oncology programs. H.C. Wainwright & Co. LLC advised in an earnings update that the firm offers significant upside potential as it is rapidly advancing its drug candidates through clinical development and is looking for ways to expand to markets outside of the U.S. H.C. Wainwright stated that it is reiterating its Buy rating and $21 price target for Nuvectis Pharma.
Hematopoietic stem cell transplantation (HSCT) and gene therapy firm Magenta Therapeutics Inc. recently announced updates related to two of its leading clinical programs. BTIG LLC advised in a research update that it expects Magenta to release updated clinical data from its MGTA-117 and MGTA-145 programs in Q4/22, which will serve as key catalysts for the company. BTIG stated it is reiterating its "Buy" rating and $6/share price target on Magenta Therapeutics.
Biotech Co. Nearing Milestones for HBV Drugs (08/15/2022)
Arbutus Biopharma Corp. presented clinical data to an international liver disease conference showing that its AB-729 continues to deliver strong reductions in HBsAg. The company is now conducting three separate combination therapy studies of its AB-729 and expects to achieve important milestones when the initial data readouts are released in H2/22. H.C. Wainwright & Co. affirmed its Buy rating for Arbutus Biopharma and adjusted its price target to $7.50.
One analyst says this healthcare co. has the opportunity to generate attractive CAPEX-light, high margin SaaS-like recurring revenues, which investors are currently getting for free, after the biotech firm entered the US market for alcohol addiction treatment through off-label licensing deals with a network of treatment clinics.
Avivagen is an early-stage life sciences company with a patented product for immune support that causes dramatic and profitable improvements in livestock. They have been increasing their sales and market penetration at a dramatic rate, and I believe them to be at an inflection point. Research coverage is expecting a 7x return.
Firm Sees Boost in Sales of Health Chewable for Dogs (08/15/2022)
Recent orders from Avivagen Inc. are helping the developer of this product build a recurring revenue stream, noted a Noble Capital Markets report.
Accelerate Diagnostics Inc. shares traded 25% higher after the company reported Q2/22 earnings and announced it entered into a commercial agreement with Becton, Dickinson and Co. that will allow it to deliver rapid antimicrobial identification and susceptibility diagnostics to clinicians and patients worldwide.
The widespread use of antibiotics in animal feeds, as well as over-prescription by physicians for therapeutic treatment of human infections, is leading to a growing resistance to antibiotics that is killing close to 1 million people each year. One company believes it has developed at least part of the solution through a beta carotene food additive that boosts immunity and contributes to better overall health.
Testing Confirms Drug Candidate Differs From Peers (08/10/2022)
Biotech ProMIS Neurosciences Inc.'s monoclonal antibody in development for Alzheimer's disease boasts a "unique" binding profile that could be "important to its clinical success," noted a Leede Jones Gable report.
With consumers moving away from artificial meat products and other preservatives, Avivagen Inc.'s antibiotic free animal feed seems to be just what they're looking for. With orders coming in and demand raising, expert Clive Maund shares his view on the potential of this life science company.
Pharma Co. Achieves Record Sales of LEMS Drug in Q2 (08/10/2022)
Shares of Catalyst Pharmaceuticals Inc. traded 24% higher to a new 52-week high after the company reported that in Q2/22 net product revenues from sales of its FIRDAPSE® increased 57.7% YoY to $53.0 million. FIRDAPSE® has been approved by both the U.S. FDA and Health Canada as a treatment for adult patients with Lambert-Eaton myasthenic syndrome, a rare autoimmune disease in which a person's immune system attacks its body's own tissues at the neuromuscular junction.
Shares of Shockwave Medical Inc. traded 17% higher to a new 52-week high after the company advised that it posted a 116% YoY increase in revenue during Q2/22 and raised the midpoint for its FY/22 revenue guidance by $25 million to $465-475 million.
Biotech Co. Awakes To Good News (08/06/2022)
Awakn Life Sciences Corp.'s rating went to an Immediate Speculative Buy after it received substantial funding from the UK government. Expert Clive Maund shares his thoughts on the development.
Biopharma Co. Planning BLA for DMD Drug (08/05/2022)
Sarepta Therapeutics Inc. recently announced that it intends to submit a BLA to the U.S. FDA for its SRP-9001, a gene therapy to treat Duchenne muscular dystrophy. Equity research firm BTIG LLC advised in a research update that SRP-9001 seems to have met the necessary criteria for receiving accelerated approval and it expects an AdCom will be established shortly. BTIG stated that it rates Sarepta Therapeutics as a "Buy" and has a $125 price target for the company's shares.
SRT Device Maker's Revenues Rise 124% in Q2 (08/05/2022)
Sensus Healthcare Inc.'s shares traded 30% higher after the company reported it achieved a 124% YoY increase in revenue in Q2/22. The company advised that demand continues to remain strong for its superficial radiation therapy (SRT) devices which provide minimally invasive and non-surgical alternatives for non-melanoma skin cancer & keloid removal.
After a few weeks of observation, expert Clive Maund believes Bion Environmental Technologies Inc. may be due for a major uptrend and is building up to a major bull market.
Shares of Senseonics Holdings Inc. traded 31.5% higher yesterday after the company reported that Elevance Health (formerly Anthem) has approved coverage of its Eversense® E3 implantable continuous glucose monitor to its forty-five million covered members.
Shares of ChemoCentryx Inc. traded 110% higher after the company reported it agreed to be acquired by Amgen Inc. for $52.00 per share in an all-cash deal valued at $4 billion. With the purchase, Amgen aims to cement its leadership position in inflammation and nephrology with the addition of ChemoCentryx's TAVNEOS® (avacopan) which the U.S. FDA approved late last year to treat ANCA-associated vasculitis, a serious autoimmune disease.
IRadimed Corp. reported Q2/22 financial results that were modestly higher than expected. ROTH Capital Partners LLC advised in a research update that based on the company's higher revenues, improved margins and disciplined cost control measures it is maintaining its Buy rating on IRadimed and raising its price target to $42/share (up from $40).
Expert Clive Maund gives his assessment of biotech Algernon Pharmaceuticals Inc. after its Phase 2 study of Ifenprodil.
Expert Believes Health Co. Blooms With Opportunity (08/02/2022)
Expert Clive Maund touches on the latest news with Bloom Health Partners Inc. from the enthusiastic buying toward the end of June to whether he believes the health company is still bullish.
Tech Co. ‘Right at the Point of Breakout' (08/02/2022)
BioLargo Inc. seemed to be very close to breaking out of its tight trading range on July 20, 2022, after remaining in the same place for a month. Expert Clive Maund goes over this update and his assessment of the company after this news.
After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis, analysts at Research Capital Corp. noted that it is maintaining its Speculative Buy rating on the company.
|"Data presented by peers at the CTAD conference are relevant to PMN."|